BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Santockyte R, Zeng J, Zheng N. Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC–MS. Bioanalysis 2019;11:785-95. [DOI: 10.4155/bio-2018-0277] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Kaur S, Alley SC, Szapacs M, Wilson A, Ciccimaro E, Su D, Henderson N, Chen L, Garofolo F, Hengel S, Jian W, Kellie JF, Lee A, Mehl J, Palandra J, Qiu H, Savoie N, Shakleya D, Staelens L, Sugimoto H, Sumner G, Welink J, Wheller R, Xue YJ, Zeng J, Zhang J, Zhou H, Wang J, Summerfield S, Kavetska O, Dillen L, Ramanathan R, Baratta M, Dasgupta A, Edmison A, Ferrari L, Fischer S, Fraier D, Haidar S, Heermeier K, James C, Ji A, Luo L, Lima Santos GM, Post N, Rosenbaum AI, Sporring S, Surapaneni S, Vinter S, Wan K, Woolf E, Kavetska O, Cho SJ, Kossary E, Prior S, Abhari MR, Soo C, Wang YM, Bandukwala A, Cherry E, Cludts I, Ghosh S, Hopper S, Ishii-Watabe A, Kirshner S, Maher K, Maxfield K, Pedras-Vasconcelos J, Saito Y, Smith D, Solstad T, Verthelyi D, Wadhwa M, Wagner L, Waxenecker G, Yan H, Zhang L. 2021 White Paper on Recent Issues in Bioanalysis: Mass Spec of Proteins, Extracellular Vesicles, CRISPR, Chiral Assays, Oligos; Nanomedicines Bioanalysis; ICH M10 Section 7.1; Non-Liquid & Rare Matrices; Regulatory Inputs (Part 1A - Recommendations on Endogenous Compounds, Small Molecules, Complex Methods, Regulated Mass Spec of Large Molecules, Small Molecule, PoC & Part 1B - Regulatory Agencies' Inputs on Bioanalysis, Biomarkers, Immunogenicity, Gene & Cell Therapy and Vaccine). Bioanalysis 2022;14:505-80. [PMID: 35578993 DOI: 10.4155/bio-2022-0078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Haulenbeek J, Beaver CJ. The impact of ligand binding based assays critical reagent characterization and storage. Bioanalysis 2021;13:797-805. [PMID: 34002637 DOI: 10.4155/bio-2020-0288] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Thankamony SP, Liu R, Peterson JE, Santockyte R, Olah T, Zhang Y. Calibrator material selection: a key criteria during biomarker assay method development. Bioanalysis 2021;13:787-96. [PMID: 33960820 DOI: 10.4155/bio-2020-0208] [Reference Citation Analysis]
4 Mayer AP, Fraley KJ. The importance of quality critical reagents for the entire developmental lifecycle of a biopharmaceutical: a pharmacokinetic case study. Bioanalysis 2021;13:817-27. [PMID: 33769084 DOI: 10.4155/bio-2020-0253] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Neubert H, Alley SC, Lee A, Jian W, Buonarati M, Edmison A, Garofolo F, Gorovits B, Haidar S, Mylott B, Nouri P, Qian M, Vinter S, Voelker T, Welink J, Wu J, Yang E, Yu H, Evans C, Summerfield S, Wang J, Bateman K, Boer J, Dean B, Dillen L, Faustino P, Ferrari L, Hughes N, Luo L, Olah T, Post N, Spellman DS, Sydor J, Zhang H, Zhang J, Zhang J, Fandozzi C, Wilson A, Fraier D, Beaver CJ, Dandamudi S, Dasgupta A, Elliott R, Ji A, Li W, McGuinness M, Lima Santos GM, Mirza T, Savoie N, Shakleya D, Sporring S, Stojdl S, Sundman P, Tampal N, Woolf E. 2020 White Paper on Recent Issues in Bioanalysis: BMV of Hybrid Assays, Acoustic MS, HRMS, Data Integrity, Endogenous Compounds, Microsampling and Microbiome (Part 1 - Recommendations on Industry/Regulators Consensus on BMV of Biotherapeutics by LCMS, Advanced Application in Hybrid Assays, Regulatory Challenges in Mass Spec, Innovation in Small Molecules, Peptides and Oligos). Bioanalysis 2021;13:203-38. [PMID: 33470871 DOI: 10.4155/bio-2020-0324] [Cited by in Crossref: 3] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
6 Yang K, Zhang Y, Chou R, Yeung L, Letarte S, Yang RS, Li X, Beaumont M, Gunawan R, Richardson D, Dellatore S, Woolf E, Xu Y. A Tiered Approach for Characterization to Ensure Quality, Reproducibility, and Long-Term Stability of Critical Reagents in Regulated Bioanalysis to Support PK/ADA/NAb Assays for Biologics and Vaccines Programs. ACS Pharmacol Transl Sci 2020;3:1310-7. [PMID: 33344904 DOI: 10.1021/acsptsci.0c00135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Zheng N, Taylor K, Gu H, Santockyte R, Wang XT, McCarty J, Adelakun O, Zhang YJ, Pillutla R, Zeng J. Antipeptide Immunocapture with In-Sample Calibration Curve Strategy for Sensitive and Robust LC-MS/MS Bioanalysis of Clinical Protein Biomarkers in Formalin-Fixed Paraffin-Embedded Tumor Tissues. Anal Chem 2020;92:14713-22. [PMID: 33047598 DOI: 10.1021/acs.analchem.0c03271] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Chen J, Zheng N. Accelerating protein biomarker discovery and translation from proteomics research for clinical utility. Bioanalysis 2020;12:1469-81. [DOI: 10.4155/bio-2020-0198] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
9 Neubert H, Shuford CM, Olah TV, Garofolo F, Schultz GA, Jones BR, Amaravadi L, Laterza OF, Xu K, Ackermann BL. Protein Biomarker Quantification by Immunoaffinity Liquid Chromatography–Tandem Mass Spectrometry: Current State and Future Vision. Clinical Chemistry 2020;66:282-301. [DOI: 10.1093/clinchem/hvz022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
10 Thankamony SP, Zhang Y. Exploratory biomarker assays: key assay parameters to evaluate in the face of evolving biomarker context-of-use. Bioanalysis 2019;11:2095-7. [DOI: 10.4155/bio-2019-0223] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]